HealthLinx Releases Data Suggesting Usefulness of Biomarker for Detection of Prostate Cancer | GenomeWeb

This story originally ran on June 30.

Australian diagnostics company HealthLinx released data last week suggesting the potential of one of its biomarkers for use as a prostate cancer diagnostic.

In a study using a well-defined set of 30 prostate cancer plasma samples and 14 male controls, researchers detected the biomarker – which HealthLinx, citing a need to protect ongoing patent applications, identified only as CM1 – in only three of the 14 control samples, while detecting elevated concentrations in 27 of the 30 prostate cancer samples.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Nature this week: variant linked to obesity risk in Samoans, health of cloned animals, and more.

Researchers explore using genome editing to treat inherited eye diseases, New Scientist reports.

Olympic athletes this summer will also undergo gene doping testing, according to Wired.

A study finds that the lower funding rate seen among women of color is more due to race than gender, according to BuzzFeed News.